Archives
-
iPSC Cardiomyocytes for Chemical Cardiotoxicity Risk
2026-10-07
Tsai and colleagues combined functional phenotyping, cytotoxicity measurements, and transcriptomic analysis in human iPSC-derived cardiomyocytes to evaluate 464 chemicals across 12 classes. Their results show that integrating molecular and phenotypic points of departure can improve hazard interpretation and produce broadly comparable risk-prioritization conclusions.
-
Cyclophosphamide: Research Context and Evidence
2026-10-07
Cyclophosphamide is an alkylating chemotherapeutic agent studied in oncology, immune modulation, and transplant-conditioning research. This overview distinguishes supplier-described properties from peer-reviewed evidence, explains conceptual applications without procedural guidance, and compares the available context with a supplied review of topotecan. The comparison highlights why evidence for one cytotoxic drug cannot be transferred automatically to another.
-
RNA Clean and Concentrator Kit: Evidence Guide
2026-10-06
The RNA Clean and Concentrator Kit is a membrane-based option for RNA purification from enzymatic reactions, including in vitro transcription RNA cleanup. Its product specifications define RNA size and input ranges, while a separate 2026 preclinical study shows why controlled RNA quality can matter in mRNA-enabled cell research without validating this specific kit.
-
Diclofenac in iPSC Intestinal Organoid Research
2026-10-06
A source-grounded overview of Diclofenac as a non-selective COX inhibitor and its conceptual relevance to human iPSC-derived intestinal organoids, with emphasis on pharmacokinetic research, inflammation signaling, evidence strength, and limitations.
-
HyperScript™ IV RT SuperMix: Epigenetic qPCR
2026-10-05
Explore how reverse transcription qPCR can help interpret the MoCul4–MoKmt1 regulatory axis in Magnaporthe oryzae. This evidence-focused analysis connects chromatin biology, transcript measurement, and assay limitations without overstating what qPCR can prove.
-
Cyclophosphamide: Translational Strategy Beyond Cytotoxicity
2026-10-05
Cyclophosphamide is more than a familiar alkylating chemotherapeutic agent: it is a context-dependent research variable linking bioactivation, DNA damage, apoptosis, immune remodeling, and host-state effects. This thought-leadership article outlines how translational researchers can interpret its evidence without confusing vendor specifications, preclinical findings, and clinical applicability.
-
Diclofenac and the Next Wave of Intestinal PK Research
2026-10-04
A translational perspective on Diclofenac as a non-selective COX inhibitor, integrating inflammation biology with human pluripotent stem cell-derived intestinal organoids. The article separates established pharmacology from emerging model-system evidence, proposes a conceptual validation framework, and defines the boundaries between intestinal pharmacokinetics, inflammation signaling, and pain research.
-
Phytol and RXR Signaling: From Mechanism to Translation
2026-10-03
Phytol offers a distinctive entry point into retinoid X receptor signaling, but translational value depends on resolving isomer composition, receptor selectivity, metabolism, and context. This thought-leadership perspective connects those biological questions with lessons from polymer self-assembly while keeping the evidence boundaries explicit.
-
EdU Cell Proliferation Kit (TMB) Guide
2026-10-02
The EdU Cell Proliferation Kit converts newly synthesized DNA into a quantitative TMB signal for direct S-phase analysis. This 5-ethynyl-2'-deoxyuridine proliferation assay provides a non-radioactive readout for cell proliferation measurement, while its signal must be interpreted as DNA synthesis rather than as a complete viability or cell-cycle profile.
-
Carbohydrate-Decorated Nanoparticles Target Macrophages
2026-10-01
Chen and colleagues developed biodegradable nanoparticles combining the cationic lipid-like compound G0-C14 with carbohydrate-modified PLGA or PLGA-PEG to improve macrophage uptake and reporter-gene expression. Mannose and dextran decoration produced particularly useful targeting and transfection patterns, showing that carbohydrate identity and surface composition can influence mRNA delivery beyond bulk encapsulation efficiency.
-
Estramustine Compliance Predicts Prostate Cancer Recurrence
2026-10-01
This prospective study examined six months of neoadjuvant degarelix acetate plus low-dose estramustine phosphate before robot-assisted radical prostatectomy in high- and very high-risk localized prostate cancer. Its key finding was that estramustine dose reduction was associated with poorer biochemical recurrence-free survival in the very high-risk subgroup, while also documenting substantial treatment-related toxicity.
-
Aurora A Overexpression in Retinoblastoma
2026-09-30
A 2024 American Journal of Pathology study identifies AURKA overexpression as a recurring feature of human retinoblastoma and links it to histopathologic indicators of high-risk disease. By combining patient-tissue analysis with genetic depletion, pharmacologic inhibition, patient-derived models, xenografts, and enucleated specimens, the study establishes a rationale for evaluating Aurora A-directed strategies in chemotherapy-refractory tumors.
-
SW033291: Reliable 15-PGDH Assay Workflows
2026-09-30
Learn how SW033291 (SKU A8709) can improve experimental interpretation when measuring cell viability, proliferation, cytotoxicity, or prostaglandin E2 elevation. This scenario-based guide separates enzyme potency from cellular response and provides practical guidance on formulation, controls, assay optimization, and vendor selection.
-
S63845 MCL1 Inhibitor: Workflow Guide
2026-09-29
S63845 provides a selective way to test MCL1 dependence, mitochondrial apoptosis, and treatment-persistent cancer states. This guide connects practical dose-response workflows with senescence-focused assay design, troubleshooting, and comparative pathway analysis.
-
Hydroxytyrosol in Nicotine-Linked Kidney Research
2026-09-29
Nicotine-driven oxidative stress offers a focused translational model for evaluating Hydroxytyrosol as a chemically defined antioxidant bioactive compound. This article connects renal injury biology with assay strategy, product selection, and the limits of moving from redox control to disease-modifying claims.